AstraZeneca

Based: London, U.K.
Announced layoffs: 550

AstraZeneca's ($AZN) job-chopping total for 2014 may pale in comparison with what the company did last year, but it's still hefty. After announcing 5,050 layoffs the year prior, the British pharma said last February it would add another 550 to the equation, bringing the overall tally to 5,600 positions.

The way AZ saw it, the reductions--as well as some operational moves to revamp its IT team and infrastructure, pull out of R&D in Bangalore, India (shedding an additional 168 jobs), and scrap branded generics in certain emerging markets--would help it squeeze $300 million out of its yearly costs. The total annual savings from the years-long restructuring? $2.5 billion, the pharma giant figured.

While the company didn't say which jobs would go and where, it did say it would nix the newly tagged 550 positions by 2016, finishing with them at the same time it wrapped the previously announced 5,050.

Of course, AstraZeneca has announced quite a few other layoffs since generics began seriously eating away at its blockbuster sales. Its restructuring--phases 1 to 3--claimed more than 20,000 jobs.

CEO Pascal Soriot has been trying to turn things around at the drugmaker since taking the helm in 2012, shortly after generic competition hit for blockbuster antipsychotic Seroquel. Meanwhile, new products haven't kicked in yet, partly because of some high-profile R&D missteps.

-- Carly Helfand (email | Twitter)

For more:
AstraZeneca steps up its global restructuring with 550 new job cuts
Generics pull AZ sales back again, but CEO promises a quicker bounce-back
AstraZeneca specialty-care execs out as commercial shake-up moves on
After Bristol-Myers R&D cuts, will AstraZeneca amp up its share of diabetes JV?
Merck, AstraZeneca, Pfizer top list of biggest pharma job-cutters
AstraZeneca to shed 5,050 jobs as it targets new growth

AstraZeneca
Read more on

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.